Of course, the original idea of Adaptive Therapy was from the visionary Robert (Bob) Gatenby at @moffittnews.bsky.social. His seminal paper: aacrjournals.org/cancerres/ar... & lots of work since, with the epicentre being @sandyanderson.bsky.social's Centre at @moffittnews.bsky.social

In other words - remarkably - it could be that less drug, less often leads to better outcomes for some patients with ovarian cancer. We eagerly await the clinical trial results - they will be definitive.

This means "adaptive therapy" where chemo dose is reduced when the tumour responds well could be a route to long-term tumour control for ovarian cancer (for certain disease types and stages). @mlockley.bsky.social is testing this in the ACTOv clinical trial: bmjopen.bmj.com/content/14/1...

With the brilliant @mlockley.bsky.social we've been exploring chemo resistance evolution in ovarian cancer. We find resistance has a fitness cost which means resistant cells are outcompeted by sensitive cells when treatment is stopped. aacrjournals.org/cancerres/ar... @icr.ac.uk @qmbci.bsky.social

Delighted that a major project of my post-doctoral fellowship in the de Bono lab has been published. A really interesting story, featuring the likes of @icrlordlab.bsky.social @boragurel.bsky.social among many others at @icrlondon.bsky.social and elsewhere.

Frequent evolution of BRCA2 reversion mutations during PARPi treatment in prostate cancer

Welcome to #bsky @alejandrapcelab.bsky.social ! Alejandra Bruna leads the paediatric cancer evolution (PCE) lab here in our @cec-icr.bsky.social. Focusing on dissecting the role of phenotypic plasticity in childhood cancer evolution and therapy response.